The transcription factor Miz1 negatively regulates TNF-induced JNK activation and cell death by suppressing TRAF2 K63-polyubiquitination; upon TNF stimulation, the suppression is relieved by Mule/ARF-BP1-mediated Miz1 ubiquitination and subsequent degradation. It is not known how Mule is activated by TNF. Here we report that TNF activates Mule by inducing the dissociation of Mule from its inhibitor ARF. ARF binds to and thereby inhibits the E3 ligase activity of Mule in the steady state. TNF induces tyrosine phosphorylation of Mule, which subsequently dissociates from ARF and becomes activated. Inhibition of Mule phosphorylation by silencing of the Spleen Tyrosine Kinase (Syk) prevents its dissociation from ARF, thereby inhibiting Mule E3 ligase activity and TNF-induced JNK activation and cell death. Our data provides a missing link in TNF signaling pathway that leads to JNK activation and cell death.
INTRODUCTION
TNF is a pleiotropic cytokine that has a critical role in apoptosis, inflammation and immune response. Dysregulation of the TNF signaling pathway has been implicated in the pathogenesis of a wide range of human diseases. 1,2 TNF binds to TNF-R1, resulting in the formation of TNF-R1 complex 1 that is composed of TNF-R1associated death domain protein, TNF-receptor-associated factor 2 and 5 (TRAF2 and 5), and receptor interacting protein 1 (RIP1), leading to activation of multiple downstream effectors including JNK (also known as stress-activated protein kinase; SAPK), as well as p38 and the IκB kinase complex. [3] [4] [5] [6] [7] [8] When NF-κB activation is impaired, JNK activation becomes prolonged, which contributes to TNF-induced apoptosis. 3, 7, [9] [10] [11] The non-receptor tyrosine kinase, Spleen Tyrosine Kinase (Syk), is potently activated in response to TNF. 12 Syk has been shown to be involved in adaptive immunity, cellular adhesion, osteoclast maturation and platelet activation. [13] [14] [15] [16] [17] [18] However, the role of Syk in TNF-induced JNK activation is poorly understood.
Mule (also known as ARF-BP1, HUWE1, Ureb1, LASU1 and HECTH9) belongs to the E5-AP C terminus (HECT) domaincontaining ubiquitin ligase (E3). It is ubiquitiously expressed in human tissues and is found to be overexpressed in certain types of cancers, including lung, breast and colorectal carcinomas. 19, 20 Mule contains three domains known to serve as protein-protein interaction sites: a UBA domain, a WWE domain, a well-conserved BH3 domain, as well as a HECT domain at its C terminus. Unlike members of other E3 families, HECT E3s process an intrinsic enzymatic ubiquitin transfer activity, which has a direct catalytic role in the final attachment of ubiquitin to the substrate proteins. It has been reported that Mule catalyzes the ubiquitination of a variety of substrates, such as p53, c-Myc, MyoD, HDAC2, E3 Histone , Mcl-1, TopBP1, Cdc6 and Pol β, thereby having an important role in cell cycle arrest, apoptosis, DNA replication, DNA damage response and repair. [19] [20] [21] [22] [23] [24] [25] [26] [27] The transcription factor Miz1 has a critical role in cell cycle arrest, proliferation, differentiation and apoptosis through transcriptional activation or repression of its target genes, including p15Ink4b, p21Cip1, Mad4 and Bcl-2. 22, [28] [29] [30] Miz1 is localized to both cytoplasm and nucleus. 29 The role of Miz1 in the nucleus has been extensively investigated. 31 However, the role of Miz1 in the cytoplasm was poorly understood. We recently reported that cytoplasmic Miz1 suppresses TNF-induced JNK1 activation and cell death through inhibition of TRAF2 K63-linked polyubiquitination. 32 The suppression is relieved by Mule, which interacts with and catalyzes K48-linked polyubiquitination of Miz1 for proteasomal degradation in response to TNF. 26 However, it is not known how Mule is activated by TNF.
The tumor suppressor ARF has been reported to directly bind to Mule and inhibit its E3 ligase activity toward p53. 19 ARF is part of an alternative transcript of the INK4b-ARF-INK4a locus. This locus encodes three proteins: p15 INK4b , p16 INK4a and ARF. In human, ARF is known as p14 ARF , and the mouse form is called p19 ARF , sharing about 50% sequence homology. ARF is involved in fundamental cellular activities, including cell cycle arrest, ribosome biogenesis, 33, 34 DNA damage response 35, 36 and autophagy. 37, 38 It has been shown that ARF is a key activator of the p53 pathway, by inhibiting p53 ubiquitin ligases Mdm2 and Mule. ARF can also induce cell cycle arrest in an Mdm2and p53-independent but Mule-dependent manner. 19 It was not known, however, whether ARF inhibits Mule-mediated Miz1 ubiquitination, and if so, how the inhibitory effect of ARF is released in response to TNF. Here, we report that TNF induces Syk-mediated tyrosine phosphorylation of Mule, which results in the dissociation of Mule from ARF, thereby activating Mule to ubiquitinate Miz1 for proteasomal degradation, providing a missing link in TNF signaling pathway that leads to JNK activation and cell death. Mule-mediated Miz1 ubiquitination  Previously, we reported that K48-linked polyubiquitination  of Miz1 by Mule triggers its proteasomal degradation, thereby  relieving Miz1 suppression on TNF-induced JNK activation and  apoptosis. 26, 32, 37, 39 Since ARF can directly bind to Mule and inhibit its E3 ligase activity toward p53, 19 we sought to determine whether ARF inhibits Mule-mediated Miz1 ubiquitination. HEK293 cells were transfected with expression vector encoding M2-Mule, which was then immunoprecipitated and used as the E3 ligase in an in vitro ubiqutination assay with GST-Xpress-Miz1 as the substrate in the absence or presence of recombinant ARF proteins. Ubiquitination of Miz1 was decreased in the presence of ARF in a dose-dependent manner, consistent with the previous report that ARF inhibits Mule ubiquitin ligase activity ( Figure 1a ). In parallel, HEK293 cells were transfected with expression vectors encoding M2-Mule and Xpress-ARF or empty vector. In vitro ubiquitination assay showed that ubiquitination of Miz1 was reduced when Mule was immunoprecipitated from cells cotransfected with ARF under non-stimulated conditions (Figure 1b ). To determine whether ARF inhibits TNF-induced Mule-mediated Miz1 ubiquitination, we silenced ARF by its specific siRNA. Knockdown of ARF enhanced the ability of TNF-stimulated Mule to ubiquitinate Miz1 in vitro ( Figure 1c ). Finally, in vivo ubiquitination assay showed that silencing of ARF increased TNF-induced K48-linked polyubiquitination of endogenous Miz1 (Figures 1d  and e ). Taken together, ARF inhibits Mule-mediated Miz1 ubiquitination.
RESULTS

ARF inhibits
ARF does not interfere with Mule-Miz1 binding Next, we determined whether ARF also regulates the interaction between Mule and Miz1. In vitro binding assay showed that the interaction between Mule and Miz1 was not affected by the addition of purified recombinant ARF (Figure 2a ). The interaction between Mule and Miz1 was enhanced in response to TNF (Figure 2b ), consistent with our previous report. 26 Silencing of ARF did not affect TNF-induced Mule-Miz1 interaction (Figure 2b) . These data suggest that ARF inhibits Mule-mediated Miz1 ubiquitination most likely through suppression of Mule E3 ligase activity instead of interfering with Mule-Miz1 binding.
TNF induces ARF-Mule dissociation
We previously reported that in response to TNF, Mule is activated and ubiquitinate Miz1. 19 It has been reported that ARF directly binds to Mule in the steady state. 19 We tested whether ARF dissociates from Mule in response to TNF, resulting in the activation of Mule. HEK293 cells were stimulated with TNF for 0, 2 and 5 min, and ARF-Mule interaction was determined by coimmunoprecipitation with Mule antibody, followed by immunoblotting with ARF antibody. The interaction between ARF and Mule was readily detected in the steady state, consistent with the previous report. 19 At 5 min after TNF stimulation, the association between ARF and Mule was dramatically decreased (Figure 3a Tyrosine phosphorylation of Mule in response to TNF is required for its dissociation from ARF An emerging theme regarding the regulation of the HECT E3 ligases is that phosphorylation of the HECT E3 ligases may increase their activity, probably by relieving the inhibitory intra-or extramolecular interactions. [40] [41] [42] [43] We sought to determine whether Mule is phosphorylated in response to TNF, thereby resulting in the release of the inhibitory ARF for Mule activation. Cells were treated with TNF for 0, 5, 8 and 10 min. Mule was immunoprecipitated followed by immunoblotting with phospho-Ser/Thr or phospho-Tyr antibody. Phosphorylation signals with the phospho-Tyr antibody were evident at 5 min, and increased by 8 and 10 min after TNF stimulation ( Figure 4a ). By contrast, we were unable to detect phosphorylation signals with the phospho-Ser/Thr antibody (data not shown). These results suggest that Mule is tyrosine phosphorylated in response to TNF.
To determine whether Mule tyrosine phosphorylation is required for the dissociation of ARF from Mule, cells were pretreated with Genistein, a tyrosine kinase inhibitor, followed by treatment with TNF at 0, 2 and 5 min. Co-immunoprecipitation assay showed that pretreatment with Genistein blocked the ARF-Mule dissociation (Figure 4b ). In addition, in vitro binding assay showed that the interaction between TNF-stimulated Mule and purified recombinant ARF was enhanced when Mule was preincubated with lambda phosphatase, which releases phosphate groups from phosphorylated residues ( Figure 4c ). These data suggest that tyrosine phosphorylation of Mule is required for ARF dissociation from Mule.
Mule tyrosine phosphorylation contributes to its E3 ligase activity Next we sought to determine whether Mule tyrosine phosphorylation positively regulates its E3 ligase activity. Cells were pretreated without or with Genistein, followed by treatment with TNF. In vitro ubiquitination assay showed that the ability of Mule to ubiquitinate Miz1 is decreased when Mule was immunoprecipitated from cells pretreated with Genistein ( Figure 5a ). It has been reported that Mule contains a consensus tyrosine phosphorylation site Y4271, and mutation of this site significantly attenuated the inhibitory effect of Mule on p53. 44, 45 We investigated whether mutation of Y4271 to nonphosphorylatable phenylalanine inhibited Mule E3 ligase activity. In vitro ubiquitination assay demonstrated that the Mule(Y4271F) mutant did not inhibit its E3 ligase activity (Figure 5b ), suggesting Y4271 of Mule is unlikely involved in the interaction of Mule with ARF.
We then searched for the potential tyrosine kinase that may phosphorylate Mule in response to TNF. A variety of tyrosine kinase inhibitors, including Piceatannol, which inhibits p56 lck and Syk; PF-562271, which inhibits focal adhesion kinase and Pyk2; and 1-Napthyl PP1, which inhibits c-Src family kinases v-Src, c-Fyn and c-Abl, were used. In vivo ubiquitination assay showed that TNF-induced Miz1 ubiquitination was decreased when cells were treated with Piceatannol ( Figure 5c ). In addition, Piceatannol prevented the dissociation of ARF from Mule in response to TNF (Figure 5d ). Furthermore, silencing of Syk reduced Miz1 ubiquitination in response to TNF (Figure 5e ). Consistently, silencing of Syk abolished the dissociation of Mule from ARF (Figure 5f ) and Mule tyrosine phosphorylation (Figure 5g ). Collectively, these data suggest that TNF-induced tyrosine phosphorylation of Mule by Syk contributes to its E3 ligase activity. To understand how Syk is activated by TNF, we determined whether Syk is recruited to TNF-R1 complex I. WT MEFs were stimulated with TNF for 1, 3 and 5 min. Syk recruitment to TNF-R1 was determined by coimmunoprecipitation with TNF-R1 antibody, followed by immunoblotting with Syk antibody (Figure 5h ). The interaction between Syk and TNF-R1 was readily detected at 1 min after TNF stimulation. Under this condition, TRAF2 was recruited to TNF-R1, consistent with previous reports. 46, 47 These data suggest that TNF may activate Syk by promoting Syk recruitment to TNF-R1, thereby contributing to JNK activation.
Mule tyrosine phosphorylation contributes to TNF-induced JNK activation and cell death Previously we reported that in response to TNF, Mule ubiquitinates Miz1 for TNF-induced JNK activation and cell death. We determined whether inhibition of Mule tyrosine phosphorylation, which is required for its activation, suppressed TNF-induced JNK activation and cell death. As expected, treatment with Genistein inhibited TNF-induced JNK activation (Figure 6a ). However, Genistein treatment did not affect TNF-induced cell death (Supplementary Figure 1A) . It is possible that Genistein has a positive role in TNF-induced cell death independently of JNK, thereby neutralizing the effect of JNK on cell death. Piceatannol treatment suppressed TNF-induced JNK activation and cell death (Figures 6b and d) . Similarly, silencing of Syk inhibited TNFinduced JNK activation and cell death (Figures 6c and e ). These data suggest that Mule tyrosine phosphorylation promotes TNFinduced JNK activation and cell death.
The regulation of the Mule-Miz1-JNK axis by ARF promoted us to determine the role of ARF in TNF-induced cell death. Interestingly, ARF − / − MEFs were resistant to TNF-induced cell death (Supplementary Figure 1B) , and silencing of ARF also decreased TNF-induced cell death (Supplementary Figure 1C) ; although under these conditions, TNF-induced JNK activation was augmented ( Supplementary Figures 1D and E) . These data suggest that ARF positively regulates TNF-induced cell death independently of the Mule-JNK axis, which overrides the effect of ARFregulated Mule-JNK axis on cell death. ARF has been reported to inhibit NF-kB activation, whereas contributes to p53 stability, 48, 49 which may account for its positive regulation of TNF-induced cell death. As ARF has a fundamental role in many cellular activities, dissecting the ARF-Mule interaction to specifically manipulate TNF-induced JNK activation/cell death might provide the therapeutic target without affecting the other functions of ARF.
DISCUSSION
The HECT-domain-containing E3 ligase Mule is the E3 ubiquitin ligase that ubiquitinates Miz1 and trigger Miz1 proteasomal degradation, thereby positively regulating TNF-induced JNK activation and cell death. 26 How Mule itself is activated by TNF is not known. Here we report that TNF induces the dissociation of ARF from Mule through Syk-mediated tyrosine phosphorylation of Mule, thereby allowing activation of the Mule-Miz1-JNK signaling pathway and cell death (Figure 7) , based on the following observations.
First, ectopic expression of ARF inhibited, whereas silencing of ARF enhanced Mule-mediated Miz1 ubiquitination in vitro and in vivo (Figure 1 ). Second, TNF induced the dissociation of ARF from Mule, which was timely correlated with Mule activation (Figure 3 ). Third, Mule was tyrosine phosphorylated in response to TNF (Figure 4 ). Finally, Syk selective inhibitor Piceatannol or silencing of Syk prevented the dissociation of ARF, thereby suppressing Mule-mediated Miz1 ubiquitination, JNK activation and cell death in response to TNF ( Figures 5 and 6) .
A number of studies indicate that Mule has complex biological effects. Chen et al. 19 conclude that Mule has an antiapoptotic function (via p53 ubiquitination and degradation), whereas Zhong et al. 27 suggest that Mule is actually proapoptotic (via Mcl-1 ubiquitination and degradation). Our studies indicate that Mule promotes apoptosis through ubiquitination and degradation of Miz1. 26, 32 It is plausible that under different pathophysiological Figure 4 . Mule is Tyrosine phosphorylated in response to TNF, which is required for ARF dissociation. (a) HEK293 cells transfected with M2-Mule were pretreated with MG-132, Okadaic Acid and Na 3 VO 4 , followed by treatment with TNF for various times as indicated. M2-Mule was immunoprecipitated followed by immunoblotting with phospho-tyrosine antibody (4G10). (b) MLE12 cells were pretreated without or with Genistein, followed by treatment with TNF for 0, 2 and 5 min. The interaction between Mule and ARF was determined by immunoprecipitation with Mule antibody, followed by immunoblotting with p19ARF antibody. (c) Immunoprecipitated M2-Mule from TNF-treated cells was preincubated without or with Lambda phosphatase, followed by the addition of purified ARF. The interaction between M2-Mule and purified ARF was determined.
conditions, Mule may target different substrates, leading to different outcomes. This is supported by the fact that the Mule gene is highly expressed in lung and breast carcinomas, 19 whereas in a recent study, Mule was shown to suppress Ras-mediated tumorigenesis by preventing the accumulation of c-Myc/Miz1 complexes, of which promoting cell cycle arrest as a barrier to malignant transformation. 50 The tumor suppressor ARF is a critical component of tumor surveillance; it functions as a checkpoint to prevent unrestricted cellular proliferation in response to aberrant oncogenic signaling. The tumor suppressive function of ARF is mainly mediated through suppression of p53 ubiquitin ligases Mdm2 and Mule, which results in p53 stabilization and p53-dependent apoptosis or cell cycle arrest. 19, 51 ARF also induce cell cycle arrest in a p53-and Mdm2-independent but Mule-dependent manner. 19 Our results demonstrated the role of the ARF-Mule pathway in the regulation of Miz1 stability, thus, Miz1 may be a downstream effector involved in the Mule-mediated but p53-independent function of ARF.
Tyrosine phosphorylation is essential for activation of Mule by TNF, which mediates the dissociation of the inhibitory ARF from Mule. Previously, it has been reported that Mule contains a consensus tyrosine phosphorylation site in its C-terminal HECT domain, 52, 53 However, our results showed that this site was not essential for TNF-induced, Mule-mediated Miz1 ubiquitination. Future studies are needed to identify the tyrosine phosphorylation site of Mule that is required for ARF dissociation and activation of Mule in response to TNF. Figure 5 . Mule tyrosine phosphorylation contributes to its E3 ligase activity. (a) In vitro self-ubiquitination of immunoprecipitated Mule from TNF-treated cells (without or with Genistein pretreatment). (b) HEK293 cells were transfected with M2-Mule(WT) or M2-Mule(M1) plasmids, followed by stimulation with TNF for various times as indicated. M2-Mule was immunoprecipitated and used for the E3 ligase in an in vitro ubiquitination assay in the absence or presence of GST-Xpress-Miz1. Self-ubiquitination of Mule was analyzed by immunoblotting with HA (ubiquitin) antibody. Ubiquitination of GST-Xpress-Miz1 was determined by GST pulldown followed by immunoblotting with HA (ubiquitin) antibody. (c and d) WT MEFs were pretreated without or with Piceatannol followed by TNF treatment. Ubiquitination of endogenous Miz1 was determined by immunoprecipitation with Miz1 antibody followed by immunoblotting with ubiquitin antibody (c). Mule-ARF interaction was analyzed by immunoprecipitation with Mule antibody followed by immunoblotting with ARF antibody (d). (e) In vivo ubiquitination of endogenous Miz1 from WT MEFs transfected with control siRNA or Syk siRNA followed by TNF treatment. (f) Mule-ARF interaction from WT MEFs transfected with control siRNA or Syk siRNA followed by TNF treatment. (g) WT MEFs co-transfected with M2-Mule and siRNA (control siRNA or siRNA for ARF) were pretreated with Okadaic Acid and Na 3 VO 4 , followed by treatment with TNF for various times as indicated. M2-mule was immunoprecipitated by M2 antibody, followed by immunoblotting with phospho-tyrosine antibody (4G10). (h) WT MEFs were treated with TNF for various times as indicated. The interaction between TNF-R1 and Syk was analyzed by immunoprecipitation with TNF-R1 antibody, followed by immunoblotting with Syk antibody.
TNF controls the dynamic interaction between ARF and Mule. Previously, it has been shown that Mule binds to numerous partners, which often regulate Mule activity, under different pathophysiological conditions. [19] [20] [21] [22] [23] [24] [25] [26] [27] In case of ARF and Mule interaction, it was reported that Mule E3 ubiquitin ligase activity is significantly inhibited by its binding partner ARF. 19 However, whether ARF-Mule interaction can be regulated by extracellular signals and, if so, how signal-induced dynamic interaction affects Mule activity was not known. Our data show that TNF controls the dynamic interaction between ARF and Mule through Sykmediated tyrosine phosphorylation of Mule, thereby regulating Mule E3 ligase activity.
Regulation of ARF-Mule interaction by Syk-mediated tyrosine phosphorylation of Mule may have broad implications. Mule is involved in many important cellular activities, including transcriptional regulation, DNA replication, DNA damage response and repair, and apoptosis. [19] [20] [21] [22] [23] [24] [25] [26] [27] Syk-mediated tyrosine phosphorylation of Mule, which disrupts ARF-Mule interaction, might be the common activation step in Mule-mediated ubiquitination of other substrates. It will be of interest to investigate whether the ARF-Mule interaction is altered under different pathophysiological conditions. The ARF-Mule interaction may also have therapeutic implications; it might represent an attractive target for manipulation of TNF-JNK signaling pathway without affecting the other functions of TNF and/or ARF.
MATERIALS AND METHODS
Reagents, plasmids and siRNAs
The antibody against Miz1 (sc-22837), ubiquitin (sc-8017), LaminA/C (sc-20681), TNF-R1 (H-5, sc-8436), TRAF2 (N-19, sc-877) and Xpress (sc-499) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibodies against phospho-JNK (4671) and Syk (2712P) were from Cell Signaling (Danvers, MA, USA). The antibody against JNK (554285) was from Pharmingen (San Diego, CA, USA). The antibody against K48-ubiquitin (05-1307) was from Millipore (Billerica, MA, USA). The antibody against Mule (4213) was from ProSci (Poway, CA, USA). The antibodies against p19 ARF (ab26696) and P14 ARF (ab11048), and the inhibitor PF-562271 (ab141360) were from Abcam (Cambridge, MA, USA). Glutathionesepharose beads (95016-984) was from GE (Pittsburgh, PA, USA). Ubiquitin aldehyde (U-201), purified E1 (U5633), cycloheximide (CHX) (C7698), MG-132 (C2211), and the antibodies against M2 (F3165), β-actin (A1978) and HA (H9658) were from Sigma-Aldrich (St Louis, MO, USA). TNF (410-MT-050) was from R&D Systems (Minneapolis, MN, USA). Recombinant E2 (UbcH5) (E2-622), and HA-ubiquitin (U-110) were from Boston Biochem (Cambridge, MA, USA). Genistein (345834), Okadaic Acid (495604) and Piceatannol (527948) were from Calbiochem (Billerica, MA, USA). 1-Naphthyl PP1 (10954) was from Cayman Chemical (Ann Arbor, MI, USA). λ-phosphatase (P0753S) was from New England Biolabs (Ipswich, MA, USA). Ni-NTA Magnetic Agarose beads (36111) were from QIAGEN (Valencia, CA, USA). GST-Miz1, Xpress-Miz1, HA-ubiquitin (WT) and M2-Mule (WT) were described previously. 26 Phosphorylation of JNK was determined. (d) WT MEFs were pretreated without or with Piceatannol, followed by treatment with TNF plus CHX for various times. Apoptotic cell death was determined. (e) WT MEFs were transfected with control siRNA or Syk siRNA, followed by treatment with TNF plus CHX for various times. Apoptotic cell death was determined. Results were presented as means ± s.e.m. and represent two independent experiments (d and e). *Po 0.05 by two-way analysis of variance. mutation was introduced into M2-Mule (WT) using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, 200521-5, Santa Clara, CA, USA). His-tagged Xpress-ARF from HEK293 cells was purified under native conditions using NiNTA Agarose beads (Qiagen), according to the manufacturer's instructions. All constructs were verified by DNA sequencing. The p14 Arf siRNA oligos (GAACAUGGUGCGCAGGUUC), p19 Arf siRNA oligos (AGGUGAUGAUGAUGGGCAA), and Syk SMARTpool siRNA (L-041084-00) were from Thermo Scientific (Waltham, MA, USA).
siRNA transfection
Cells were transfected with the scrambled siRNA control (siCtrl), or ARF siRNA (20 nM for WT MEFs and MLE12 cells; 100 nM for HEK293 cells), or Syk siRNA (200 nM for WT MEFs). After 24 h, cells were serum-starved for 24 h followed by treatment with TNF.
Cell culture, transfection and apoptosis assays
Cell culture conditions and transfections were described previously. 54, 55 siRNAs were transfected using Lipofectamine 2000 (Invitrogen, 52887, Waltham, MA, USA). Plasmids were transfected using Turbofect (Thermo Scientific, R0531). Apoptosis assays were performed as we described previously. 32, 56, 57 Co-immunoprecipitation Cell extracts were prepared using the co-IP buffer (20 mM Tris, pH 7.6, 100 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40, 1 mM DTT, 10 mM p-nitrophenyl phosphate, 1 μg/ml aprotinin and 1 mM Na 3 VO 4 ) and incubated with specific antibody pre-coupled with Protein A Sepharose beads for overnight at 4°C. Immune complexes were washed with co-IP buffer three times, and then analyzed by immunoblotting.
In vitro ubiquitination assay
Purified GST-Xpress-Miz1 (100 ng) was incubated with E1 (100 ng), E2 UbcH5 (500 ng), ubiquitin (10 μg) and immunoprecipitated Mule, in an ATP-regenerating system (50 mM Tris, pH 7.6, 5 mM MgCl2, 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml creatine kinase and 0.6 U/ml inorganic pyrophosphatase) in the presence of MG-132 (50 μM) at 37°C for 1 h.
In vivo ubiquitination assay
Cells were pretreated with MG-132 (50 μM) for 4 h before TNF stimulation. Cells were harvested with 150 μl M2 buffer (20 mM Tris, pH 7.6, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 0.5% Nonidet P-40, 1 mM DTT, 1 μg/ml aprotinin, 10 mM p-nitrophenyl phosphate, 1 mM Na 3 VO 4 , 0.8 mM NEM and 5 μM ubiquitin aldehyde), followed by the addition of SDS to a final concentration of 1% and boiled for 5 min. Cell extracts were then diluted 10-fold in M2 buffer before immunoprecipitation. Ubiquitinated proteins were analyzed by immunoblotting with ubiquitin antibody.
Statistical analysis
Data were analyzed by two-way analysis of variance, P-values as indicated, with the assumption of normal distribution of data and equal sample variance. Sample sizes were selected on the basis of preliminary results to ensure an adequate power. All cells used for the study were included for the statistical analysis, with no randomization or blinding involved. No exclusion of data points was used.
